Krystal Biotech grants director options, RSUs

Krystal Biotech director Everett Rand Sutherland received new stock option and RSU awards that vest in full in September 2027, reflecting routine board compensation.

Rhea-AI Filing Summary

Krystal Biotech, Inc. (symbol: KRYS) is the issuer of record for a Form 4 filing submitted to the SEC. Sutherland Everett Rand reported acquisition or exercise transactions in this Form 4 filing.

Krystal Biotech, Inc. (KRYS) reported that director Everett Rand Sutherland received equity awards on September 14, 2026. He was granted 1,187 stock options to buy common stock at $340.03 per share, vesting in full on September 14, 2027, and 471 restricted stock units, also vesting in full on that date, in each case subject to continued Board service and earlier vesting conditions under the company’s Non-Employee Director Compensation Policy.

Insider Trade Summary

Grant/Award: 1,658 shares

Grant/Award 2 txns

Insider Sutherland Everett Rand

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	1,187	$0.00	$0.00
Grant/Award	Restricted Stock Units F2, F3	471	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,187 contracts (Direct); Restricted Stock Units — 471 contracts (Direct)

Footnotes (3)

1. F1. The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
2. F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. F3. The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Key Figures

Stock options granted: 1,187 options Option exercise price: $340.03 per share Options vesting date: September 14, 2027 +5 more

8 metrics

Stock options granted 1,187 options Grant to director Everett Rand Sutherland on September 14, 2026

Option exercise price $340.03 per share Strike price for 1,187 stock options granted September 14, 2026

Options vesting date September 14, 2027 Full vesting date for the 1,187 stock options, subject to service conditions

Options post-transaction holdings 1,187 options Total stock options held directly after the reported grant

RSUs granted 471 RSUs Grant to director Everett Rand Sutherland on September 14, 2026

RSUs vesting date September 14, 2027 Full vesting date for the 471 RSUs, subject to service conditions

RSUs post-transaction holdings 471 RSUs Total restricted stock units held directly after the reported grant

Option expiration date September 13, 2036 Expiration date for the 1,187 stock options granted

Key Terms

Restricted Stock Units, Non-Employee Director Compensation Policy, Stock Option

3 terms

Restricted Stock Units financial

"The RSUs vest in full on September 14, 2027, subject to continued service"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Non-Employee Director Compensation Policy financial

"described in the Company's Non-Employee Director Compensation Policy as in effect"

Stock Option financial

"The stock options vest in full on September 14, 2027, subject to continued service"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did KRYS grant to director Everett Rand Sutherland?

Everett Rand Sutherland received 1,187 stock options with a strike price of $340.03 and 471 restricted stock units, each RSU representing one share of Krystal Biotech common stock, as part of his compensation as a non-employee director.

When do Everett Rand Sutherland’s new KRYS stock options vest?

The 1,187 stock options granted to Everett Rand Sutherland vest in full on September 14, 2027, subject to his continued service on Krystal Biotech’s Board of Directors and earlier vesting in certain circumstances under the Non-Employee Director Compensation Policy.

When do Everett Rand Sutherland’s KRYS restricted stock units vest?

The 471 restricted stock units granted to Everett Rand Sutherland vest in full on September 14, 2027, provided he continues to serve on Krystal Biotech’s Board through that date, with potential earlier vesting in situations described in the company’s Non-Employee Director Compensation Policy.

How many KRYS shares can be acquired from Everett Rand Sutherland’s new option grant?

The new option grant allows Everett Rand Sutherland to acquire 1,187 shares of Krystal Biotech common stock upon exercise, at an exercise price of $340.03 per share, before the option’s stated expiration on September 13, 2036.

Were Everett Rand Sutherland’s KRYS transactions under a Rule 10b5-1 trading plan?

No. The filing indicates the Rule 10b5-1 checkbox is not affirmed, and the transactions are reported as grants/awards of options and restricted stock units rather than trades executed under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 08:03 PM Accepted by SEC EDGAR 09/16/2026 - 08:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sutherland Everett Rand

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PENNSYLVANIA 15203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$340.03	09/14/2026		A		1,187		(1)	09/13/2036	Common Stock	1,187	$0	1,187	D
Restricted Stock Units	(2)	09/14/2026		A		471		(3)	(3)	Common Stock	471	$0	471	D

Explanation of Responses:

1. The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

3. The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Remarks:

	/s/ Krish Krishnan, as attorney-in-fact for Everett Rand Sutherland	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)